Actively Recruiting
Phase II Study of Oral Asciminib for Adults with Chronic Myeloid Leukemia in Chronic or Accelerated Phase Carrying the T315I Mutation Who Are Resistant, Intolerant, or Cannot Use Ponatinib
Led by Novartis Pharmaceuticals · Updated on 2026-04-21
20
Participants Needed
6
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the potential of asciminib, an investigational drug, to manage chronic myeloid leukemia in chronic phase CML-CP or accelerated phase CML-AP in patients who carry the T315I mutation. This mutation makes treatment difficult due to limited options. The study aims to collect data on how effective and safe asciminib is for these patients, addressing an unmet medical need and possibly offering a new treatment path for those resistant, intolerant, or ineligible to ponatinib. This Phase II, multi-center, open-label, single-arm study will give patients oral asciminib at a dose of 200 mg twice daily. The dose can range from 200 mg to 400 mg daily. The study has two phases the core phase, which focuses on answering the primary scientific and medical questions, and an extension phase, which allows participants to continue treatment up to the drugs commercialization or a decision not to proceed with marketing. Participants will be monitored over time with assessments including the level of BCRABL1 gene expression to measure molecular response at various months up to 24 months. Researchers will also track overall survival, progression-free survival, and adverse events. Safety and effectiveness will be evaluated throughout, with participants followed up for up to two years after starting treatment.
CONDITIONS
Brief Title
Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here